Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
Open Access
- 1 September 2017
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (9)
- https://doi.org/10.1128/aac.00700-17
Abstract
Cefiderocol (S-649266), a novel siderophore cephalosporin, shows potent activity against carbapenem-resistant Gram-negative bacilli. In this study, we evaluated the efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli ( Pseudomonas aeruginosa , Acinetobacter baumannii , and Klebsiella pneumoniae ) in immunocompetent-rat respiratory tract infection models recreating plasma pharmacokinetics (PK) profiles in healthy human subjects. A total of 6 clinical isolates (1 cephalosporin-susceptible P. aeruginosa isolate, 1 multidrug-resistant P. aeruginosa isolate, 2 multidrug-resistant A. baumannii isolates, and 2 carbapenem-resistant K. pneumoniae isolates) were evaluated. Four-day treatment with a human exposure of 1 g ceftazidime every 8 h as a 0.5-h infusion showed potent efficacy only against a ceftazidime-susceptible isolate, not against five ceftazidime-resistant isolates harboring carbapenemase. With cefiderocol, a human exposure of 2 g every 8 h as a 3-h infusion for 4 days produced a >3 log 10 reduction in the number of viable cells of these carbapenem-resistant isolates in the lungs. When the infusion time was 1 h, bactericidal activity was also observed against all isolates tested, although for 2 of 5 carbapenem-resistant isolates, a 3 log 10 reduction was not achieved. The difference in efficacy achieved by changing the infusion period from 1 h to 3 h was considered to be due to the higher percentage of the dosing interval during which free-drug concentrations were above the MIC (% fT MIC ), as observed for β-lactam antibiotics. These results suggest the potential utility of cefiderocol for the treatment of lung infections caused by carbapenem-resistant P. aeruginosa , A. baumannii , and K. pneumoniae strains.Keywords
This publication has 22 references indexed in Scilit:
- In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant StrainsAntimicrobial Agents and Chemotherapy, 2016
- Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesDiagnostic Microbiology and Infectious Disease, 2013
- Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategiesJournal of Antimicrobial Chemotherapy, 2012
- Multidrug Resistance among Gram-Negative Pathogens That Caused Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2006–2008Infection Control & Hospital Epidemiology, 2010
- Multidrug-Resistant Gram-Negative InfectionsDrugs, 2009
- Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USAJournal of Antimicrobial Chemotherapy, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial InfectionsClinical Infectious Diseases, 2005
- Comparative Bacteriological Efficacy of Pharmacokinetically Enhanced Amoxicillin-Clavulanate against Streptococcus pneumoniae with Elevated Amoxicillin MICs and Haemophilus influenzaeAntimicrobial Agents and Chemotherapy, 2005
- A simple non-surgical method of intrabronchial instillation for the establishment of respiratory infections in the ratLaboratory Animals, 1991